Table 1. Evidence of Interaction Between Pre-Treatment Histology and Effect of Treatment on SVR

Author	Tx Group	N	Histology Variable	Calculated odds ratio for SVR for	95% CI
Manns, 2001	A: High dose Peg-IFN 1.5 mg/kg qw + RBV	469	No/Minimal Fibrosis	Tx Effect: 1.20	(0.97, 1.49)
			Bridging Fibrosis/Cirrhosis	Histology Effect: 1.10	(0.96, 1.26)
				Tx - Histology Effect: 1.14	(0.87, 1.51)
	B: Low dose Peg-IFN 0.5 mg/kg qw + RBV	491			
	C: IFN alpha-2b + RBV	468			
Zeuzem, 2000	A:IFN + Amantadine	59	No/mild/mod fibrosis	Tx Effect: 0.41	(0.14, 1.19)
			Severe fibrosis	Histology Effect: 1.39	(0.28, 7.02)
	B: IFN + Placebo	60		Tx - Histology Effect: unable to calculate	
Heathcote, 2000	A: IFN alpha-2a	88	Total HAI ≤ 10	Tx Effect: 0.83	(0.37, 1.85)
			HAI > 10	Histology Effect: 0.41	(0.21, 0.80)
	B: Peg IFN alpha-2a 90 µg qw	96		Tx - Histology Effect: 0.32	(0.74, 1.38)
	C:Peg IFN alpha-2a 180 µg qk	87	Cirrhosis	Tx Effect: 1.22	(0.62, 2.42)
			Bridging fibrosis	Histology Effect: 0.64	(0.41, 1.00)
				Tx - Histology Effect: 1.58	(0.65, 3.86)
Mangia, 2001a	A: IFN alpha-2a	101	Grade 1-2	Tx Effect: 0.52	(0.26, 1.05)
			Grade 3	Histology Effect: 1.69	(0.57, 4.86)
	B: IFN alpha-2a + Amantadine	99		Tx - Histology Effect: 1.77	(0.21, 14.7)
			Stage 0-1	Tx Effect: 0.54	(0.26, 1.10)
			Stage 2-4	Histology Effect: 2.04	(0.97, 4.30)
				Tx - Histology Effect: 1.18	(0.27, 5.24)

Table 1. Evidence of Interaction Between Pre-Treatment Histology and Effect of Treatment on SVR (continued)

Author	Tx Group	N	Histology Variable	Calculated odds ratio for SVR for	95% CI
Mangia, 2001	A: IFN alpha-2b	96	Stage 0-1	Tx Effect: 0.24	(0.13, 0.46)
			Stage > 1	Histology Effect: 1.36	(0.64, 2.87)
	B: IFN alpha-2b + RBV	96		Tx - Histology Effect: 10.73	(2.37, 48.6)
Berg, 2000	A :IFN + RBV	93	grade ≤ 1	Tx Effect: 0.59	(0.28, 1.23)
			grade > 1	Histology Effect: 1.20	(0.52, 2.81)
	B:IFN	92		Tx - Histology Effect: 0.364	(0.67, 1.98)
			stage ≤ 1	Tx Effect: 0.512	(0.23, 1.15)
			stage > 1	Histology Effect: 2.73	(1.06, 7.00)
				Tx - Histology Effect: 0.323	(0.05, 2.13)

Table 2: Evidence of Relation Between HCV Genotype and Treatment Effect on Sustained Virological Response

Author, Year	HCV Genotype	Treatment Groups	SVR n (%)	Odds Ratio (95% CI) For Treatment Effect (T), Genotype Effect (G), Treatment-Genotype Interaction (I)*		
Barbaro, 1999	1b	IFN beta	10 (22)	T:	4.2	(1.3-28.3)
		IFN alpha + RBV	1 (2)	G:	0.11	(0.01-0.57)
	2a/c	IFN beta	4 (9)	I:	0.05	(0.00-0.39)
		IFN alpha + RBV	9 (20)			
	3a	IFN beta	3 (25)			
		IFN alpha + RBV	2 (15)			
Zeuzem, 2000	1	PEG	2 (5)	T:	0.41	(0.10-1.3)
		IFN	5 (11)	G:	0.17	(0.05-0.59)
	non-1	PEG	4 (24)	I:	1.06	(0.12-11.4)
		IFN	8 (42)			

Table 2. Evidence of Relation Between HCV Genotype and Treatment Effect on Sustained Virological Response (continued)

Author, Year	HCV Genotype	Treatment Groups	SVR n (%)	Odds Ratio (95% CI) For Treatment Effect (T), Genotype Effect (G), Treatment-Genotype Interaction (I)*		
Payen, 1998	1	IFN 3 mu tiw 6 mos	3 (11)	T:	1.10	(0.56-2.3)
		IFN 3 mu tiw 12 mos	1 (4)	G:	0.15	(0.05-0.36)
			2 (8)	I:	0.77	(0.23-2.4)
	2	IFN 3 mu tiw 6 mos	1 (13)			
		IFN 3 mu tiw 12 mos	5 (46)			
		IFN 10 mu tiw 6 mos	1 (13)			
	3	IFN 3 mu tiw 6 mos	2 (20)			
		IFN 3 mu tiw 12 mos	11 (73)			
		IFN 10 mu tiw 6 mos	5 (30)			
	4	IFN 3 mu tiw 6 mos	1 (20)			
		IFN 3 mu tiw 12 mos	1 (33)			
		IFN 10 mu tiw 6 mos	1 (25)			
Mangia, 2001	1/4/5	IFN	7 (13)	T:	0.25	(0.12-0.50)
		IFN + RBV	17 (38)	G:	0.28	(0.12-0.62)
	2/3	IFN	15 (37)	I:	1.10	(0.30-4.2)

Table 2. Evidence of Relation Between HCV Genotype and Treatment Effect on Sustained Virological Response (continued)

Author, Year	HCV Genotype	Treatment Groups	SVR n (%)	Odds Ratio (95% CI) For Treatment Effect (T), Genotype Effect (G), Treatment-Genotype Interaction (I)*		
		IFN + RBV	35 (69)			
Manns, 2001	1	High dose PEG + RBV	145 (42)	T:	1.18	(1.03-1.35)
		Low dose PEG + RBV	118 (34)	G:	0.17	(0.13-0.22)
		IFN + RBV	114 (33)	I:	0.94	(0.70-1.3)
	2/3	High dose PEG + RBV	121 (82)			
		Low dose PEG + RBV	122 (80)			
		IFN + RBV	115 (79)			
	4/5/6	High dose PEG + RBV	8 (50)			
		Low dose PEG + RBV	4 (33)			
		IFN + RBV	6 (38)			
Heathcote, 1998	1	IFN 24 weeks	7 (9)	T:	0.32	(0.14-0.68)
		IFN 48 weeks	14 (19)	G:	0.20	(0.08-0.52)
	2	IFN 24 weeks	1 (9)	I:	0.39	(0.08-1.9)
		IFN 48 weeks	5 (42)			
	3	IFN 24 weeks	4 (22)			

Table 2. Evidence of Relation Between HCV Genotype and Treatment Effect on Sustained Virological Response (continued)

Author, Year	HCV Genotype	Treatment Groups	SVR n (%)	Odds Ratio (95% CI) For Treatment Effect (T), Genotype Effect (G), Treatment-Genotype Interaction (I)*		
		IFN 48 weeks	8 (66)			
Heathcote, 2000	1	IFN	1 (2)	T:	0.40	(0.20-0.74)
		Low Dose PEG	3 (5)	G:	0.14	(0.05-0.32)
		High Dose PEG	6 (13)	I:	1.10	(0.39-3.6)
	non-1	IFN	6 (15)			
		Low Dose PEG	10 (28)			
		High Dose PEG	19 (49)			
Chapman, 2001	1	IFN	5 (45)	T:	2.00	(0.36-16.6)
		IFN + RBV	1 (17)	G:	0.11	(0.00-0.99)
	non-1	IFN	2 (50)	I:	0.12	(0.00-3.3)
		IFN + RBV	6 (67)			
Di Marco, 2000	1b	IFN + RBV 6 mos	5 (26)	T:	0.22	(0.05-0.81)
		IFN + RBV 12 mos	12 (67)	G:	0.33	(0.02-2.4)
	non-1b	IFN + RBV 6 mos	4 (67)	I:	1.90	(0.06-37.5)
		IFN + RBV 12 mos	6 (86)			

Table 2. Evidence of Relation Between HCV Genotype and Treatment Effect on Sustained Virological Response (continued)

Author, Year	HCV Genotype	Treatment Groups	SVR n (%)	Odds Ratio (95% CI) For Treatment Effect (T), Genotype Effect (G), Treatment-Genotype Interaction (I)*		
Sarracco, 2001	1/4	IFN 3 mu + RBV 12 mos	9 (9)	T:	1.0	(0.82-1.2)
		IFN 5 mu + RBV 12 mos	20 (18)	G:	0.29	(0.18-0.47)
		IFN 3 mu + RBV 6 mos	7 (7)	I:	0.97	(0.65-1.4)
		IFN 5 mu + RBV 6 mos	14 (12)			
	2/3	IFN 3 mu + RBV 12 mos	12 (32)			
		IFN 5 mu + RBV 12 mos	16 (30)			
		IFN 3 mu + RBV 6 mos	12 (30)			
		IFN 5 mu + RBV 6 mos	13 (35)			

Footnotes:

* Odds ratio refers to the odds of a sustained virological response with HCV genotype 1 compared to other HCV geneotypes
CI, confidence interval
HCV, hepatitis C virus
IFN, standard interferon
PEG, peg-interferon
RBV, ribavirin
SVR, sustained virological response
mos, months
mu, million units
tiw, three times a week